Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T00:16:31.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect a new version of a clinical trial study on pembrolizumab and eribulin for HR-positive/HER2-negative metastatic breast cancer, with significant changes in the study description and investigator details.
    Difference
    44%
    Check dated 2025-04-22T18:12:58.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 19, 2025.
    Difference
    0.4%
    Check dated 2025-04-08T09:18:58.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The page has updated its version information from v2.14.2 to v2.14.3 and has changed the dates associated with the results and last update from February 19, 2025, to March 25, 2025.
    Difference
    0.3%
    Check dated 2025-04-01T05:45:01.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    The webpage has been updated to include new clinical trial results regarding the efficacy of Pembrolizumab in combination with Eribulin, detailing various metrics such as overall survival and progression-free survival in patients with PD-L1 positive tumors. Additionally, several outdated results and references have been removed.
    Difference
    21%
    Check dated 2025-02-24T09:54:55.000Z thumbnail image
  8. Check
    99 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-10T01:51:22.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.